Exchange: NYSEArca·Updated 07:59 PM EST

FHLC News

News
all
press releases
More News
Vinay Prasad told Bloomberg that the FDA is going to be “extremely flexible” regarding gene editing therapies.
Stocktwits
UNH posts mixed Q3 results with a revenue miss but lifts its 2025 EPS outlook, boosting interest in healthcare ETFs like IHF and XLV.
Zacks
JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.
Zacks
The company stated that the continued effects and consistent benefits observed with repeat dosing in the trial support the potential of BXCL501 for use in the outpatient setting.
Stocktwits

Advertisement|Remove ads.